# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹372 Cr** Q2 (+7%) · **₹700 Cr** H1 (+8%) * **EBITDA:** **₹110 Cr** Q2 (+21%) · **₹208 Cr** H1 (+20%) * **EBITDA Margin:** **30%** Q2 (+400 bps) · **30%** H1 (+300 bps) * **PAT:** **₹44 Cr** Q2 · **₹91 Cr** H1 ## B. Revenue Growth * **Record Top-Line Performance:** Highest-ever quarterly and H1 revenues achieved, driven by scale-up in complex products and strong demand across segments. * **Service Income Clarity:** Total service income of ₹72 Cr includes ₹46 Cr from Formulations and **₹26 Cr** from CDMO development and licensing, with API sales breakout to be provided post-call. ## C. Gross Margin * **Margin Resilience:** Gross margin expanded to 72% in Q2 and 74% in H1 despite lower CDMO and licensing contributions, reflecting strong underlying profitability from complex product scale-up. ## D. EBITDA & PAT * **Profitability Milestone:** Q2 PAT of ₹44 Cr and H1 PAT of ₹91 Cr surpassed full-year FY’25 earnings, underscoring significant bottom-line leverage. * **ROCE Expansion:** Adjusted ROCE improved sharply to **~17%** in H1 FY’26 from 4% in FY’23, with further gains expected as biologics scale and business mix improves. ## E. Cash Flow & Capex * **Self-Funded Growth:** Interest outgo has stabilized, and capex is expected to be largely funded through internal accruals, supporting capital discipline. --- # 2. Product & Therapy Performance ## A. Key Figures * **API Turnover:** **₹205 Cr** non-captive (driven by expanded capacities) * **Biologics Revenue:** **₹25 Cr** Q2 FY26 · **₹61 Cr** H1 FY26 * **Formulation Revenue:** **₹109 Cr** Q2 FY26 (+16% YoY) * **Service Income:** **₹72 Cr** (includes CDMO, licensing, and other operating income) ## B. API Business * **Strategic Growth Trajectory:** API division maintains strong double-digit YoY growth momentum, anchored in high-barrier segments and integrated capabilities across oncology, peptides, and polymers. * **Commercial & Development Strategy:** NorUDCA partnered with **three companies**—a capped model to prevent internal competition—while Semaglutide development advances via **dual synthetic/semisynthetic pathways**, leveraging backward integration and captive formulation demand. * **Innovation Pipeline:** Multiple polymer programs in early development, with commercial supply already established to **big pharma customers**, signaling technical validation and market traction. ## C. Biologics Revenue * **Emerging Scale:** Biologics business demonstrates accelerating revenue execution, delivering robust H1 performance despite limited contribution from Adalimumab in India. * **Capability Signaling:** Adalimumab launch achieved **high-concentration, differentiated formulation** with solid market share, serving as a strategic proof point for internal biologics proficiency. ## D. Formulation Launches * **First-in-Class Launch:** Successful commercialization of **NorUrsodeoxycholic Acid**, the company’s first NCE in India and a global first launch by Shilpa Medicare, marks a milestone in proprietary innovation. * **Differentiated Pipeline:** Long-acting Ondansetron injection targets high-emetic-risk patients on **paclitaxel/taxanes**, entering the long-acting antiemetic space as a novel formulation competing with Palonosetron. ## E. NCE & 505(b)(2) Programs * **High-Value Partnerships:** API supply for a **confidential NCE program** with a big pharma partner set for commercialization in **FY26 and FY27**, representing a sizable, undisclosed growth opportunity. --- # 3. Pipeline & Clinical Progress ## A. Key Figures * **Biosimilar Pipeline:** **8 programs** in development, with **Aflibercept** most advanced (Phase III) * **CDMO Programs:** **6 active** biologics CDMO programs underway * **505(b)(2) Programs:** **5 additional** differentiated programs in pipeline * **NBE Programs:** **2 new** collaborations (mAbTree, Alveolus) planned for Phase I in FY '27 ## B. Phase III Trials * **Pivotal Milestones Achieved:** Ondansetron long-acting injection completed Phase III, with **India filing planned for Q4 FY'26** and launch in the following year. * **Global Trial Expansion:** NorUDCA Phase III trials for U.S. and Europe set to begin in next fiscal; U.S./Europe Phase III for Albumin targeted for FY '27. * **Trial Resumption:** Phase III for Androgenic Alopecia to restart in **first half of next fiscal** after preclinical delays. * **Regional Protocol Clarity:** Albumin European Phase III protocol revised and under review; Indian trial protocol approved January 2025. * **Dual Trial Registration:** Two separate CTRI NIC registrations confirmed for India and Europe Albumin studies. ## C. Regulatory Submissions * **Near-Term Approvals Expected:** Rotigotine patch on track for **European approval in Q4 FY'26**, with U.S. submission in Q3 FY'26. * **Regulatory Momentum:** Recombinant Human Albumin IMPD submission underway; European Phase III initiation expected by **Q3 FY'26**. * **Filing Pipeline:** Two additional transdermal patches targeted for filing in next financial year. ## D. CDMO Development * **Stable CDMO Base:** Biologics division maintains **6 active development programs**, supporting external partners. ## E. Biologics Pipeline * **NCE Commercialization Imminent:** First NCE product approved by customer; **commercial supply expected from Q4 FY'26**. * **Next-Gen Pipeline Advancing:** First ADC biosimilar and two NBE programs (mAbTree, Alveolus) targeted to enter **Phase I human studies in FY '27**. * **Innovation Expansion:** New ADC biosimilar represents **distinct pipeline addition** beyond current peptide focus. --- # 4. Manufacturing & Capacity ## A. Peptide Expansion * **Capacity Ramp-Up:** Tranexamic Acid scaling to full utilization this year, with **100 MT expansion** underway and commissioning set for next fiscal. * **CDMO Momentum:** Peptide and polymer programs advancing, including dedicated facility for Lanthanum Dioxycarbonate (Unicycive) commissioning in **Q3 FY'26** and commercial launch expected the following year. * **Semaglutide Progress:** Development complete, **process validation batches initiated**, with full PV campaign on track for **Q4 FY'26**. * **Long-Term Peptide Scaling:** A large, fully automated peptide facility under construction, commissioning planned for next fiscal, reinforcing CDMO leadership. * **R&D Foundation:** Multi-year investment in peptide R&D supports current operations across **2 dedicated manufacturing lines**, with new site revenues expected in **H2 FY'27** post-approval. ## B. Dedicated Facilities * **Strategic Complexity Edge:** Shilpa’s focused investments in Biologics, transdermal, and Albumin fermentation establish a rare, high-barrier platform beyond standard CDMO capabilities. * **Differentiated Polymer Expertise:** Company possesses **rare capability** in manufacturing uniform, high-purity polymers—distinctive among Indian players and global CDMOs. ## C. Capex Plans * **H1 Spending Confirmed:** Capex of **₹153–165 Cr** in first half, primarily directed toward Albumin and API capacity, despite underutilization in Biologics/biosimilars. * **Forward Capex Clarity Lacking:** No detailed breakdown or formal program disclosed for FY'26 and FY'27 beyond ongoing projects. --- # 5. Geography & Market Mix ## A. Key Figures * **Base Business Growth:** **60%** Q2 YoY · **67%** H1 YoY (ex. licensing) ## B. U.S. Filings & Launches * **Accelerating U.S. Momentum:** Robust growth driven by rising market share in complex generics, supported by **2 new product filings** and **1 PV completion** in the quarter. * **Commercial Execution:** All **3 prior-year NDA-approved products** now launched in the U.S., with Pemetrexed showing strong uptake and two others gaining gradual traction. * **Strategic Launch Model:** 505(b)(2) portfolio being commercialized via **USFDA-approved third-party CMOs**, insulating from U.S. tariff risks. * **Global Expansion Pipeline:** NorUrsodeoxycholic Acid set for global launch, reinforcing innovation-led growth strategy. ## C. European Market Growth * **Sustained Market Share Gains:** Nilotinib continues to deliver **quarterly market share growth** in Europe with minimal near-term generic competition. * **Revenue Inflection:** European formulation revenues surged in H1, led by differentiated Nilotinib launch performance. * **Regulatory & Commercial Progress:** Ursodeoxycholic Acid received **CEP approval**, with commercial supplies expected in **Q3 FY'26**. * **Pipeline Ambition:** Strategy centered on **3–5 complex generics** targeting **INR300–400 Cr** in annual formulation revenues. ## D. India Commercialization * **First-Mover Innovation:** Launch of **NorUDCA**, a novel NCE for NAFLD, marks Shilpa’s debut as a first-mover in India with **significant market potential** and **10–20% share target**. * **Commercial Rollout Underway:** API supplies to begin in **Q3 FY'26**; partnered launch via **three marketing companies**, with own brand planned but longer ramp-up expected. * **Revenue Model Clarity:** No profit-sharing; revenues based on **supply price agreements**, ensuring predictable margin structure. * **Strategic Partnerships:** Collaborations with **leading Indian firms** enable strong reach into specialty hospitals and physician networks. * **Next-Gen Pipeline Signal:** Long-acting Ondansetron injection completed **Phase III trials**, with regulatory filing imminent despite early-stage market visibility. --- # 6. Client & Regulatory Risks ## A. USFDA Import Alert * **No Update on FDA Alert:** Management confirms **no new developments** regarding the USFDA import alert; disclosures will follow if material changes occur. ## B. Licensing Variability * **Licensing Decline Explained:** Year-on-year decrease in licensing income reflects **successful transition of products to commercial supply**, not operational issues. * **Inherent Revenue Lopsidedness:** Licensing income is **inherently uneven** across periods due to pipeline stage dynamics, limiting comparability. ## C. Tariff Impacts * **Resilient US Market Position:** Existing U.S.-bound products show **no tariff-related challenges or market share erosion**. * **Differentiation Required in Europe:** In the **highly competitive** European oncology injectables market, success hinges on **complex or differentiated generics**, not me-too offerings. * **NorUDCA Competitive Edge:** NorUDCA holds a **strategic advantage** in NAFLD due to limited competition despite alternative therapies. --- # 7. Guidance & Outlook ## A. Key Figures * **Capex Guidance:** **₹75–100 Cr** for FY '26 ## B. Revenue Forecast * **Licensing Income Visibility:** Partial receipt achieved; remainder tied to **year-on-year milestones** by marketing partners across upcoming quarters. * **NorUDCA Revenue Profile:** Expected to contribute primarily through **sales revenue** with initial supply in **Q3–Q4**, and meaningful impact from next financial year. * **OLC Contract Monetization:** Commercial revenue anticipated next year post-approval, with company as **exclusive supplier**, though volume and financial details remain undisclosed. ## C. Launch Timelines * **OLC Commercialization Timing:** Launch expected in **second half of next financial year**, contingent on regulatory review of new facility data—no guarantee of timeline. * **Peptide Project Milestone:** Significant potential confirmed; pilot supply completed via MNC partner, with **commercialization targeted for 2027**. * **Semaglutide Development Track:** Product readiness expected by **Q4**, with regulatory filing planned in **H1 FY '27**. * **Ondansetron Partnership Outlook:** Early-stage discussions underway; investors to receive **greater clarity in upcoming quarters** on market potential and launch strategy. ## D. Margin Sustainability * **Profitability Drivers:** Sustained margins expected due to **improved business mix**, rising base business share, and novel product launches like NorUDCA. * **Cost Resilience Framework:** Agile systems in place to counter rising input and compliance costs, supported by **smarter sourcing, pricing discipline, and operational efficiencies**.